Efficacy of zoledronic acid in Erdheim-Chester disease: A case report.

[1]  C. Thorns,et al.  Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib. , 2015, Rheumatology.

[2]  S. Ferretti,et al.  Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. , 2015, Blood.

[3]  G. Ingravallo,et al.  Erdheim-Chester disease: a systematic review. , 2015, Critical reviews in oncology/hematology.

[4]  V. Baykov,et al.  Rare Form of Erdheim-Chester Disease Presenting with Isolated Central Skeletal Lesions Treated with a Combination of Alfa-Interferon and Zoledronic Acid , 2015, Case reports in hematology.

[5]  P. Grenier,et al.  Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  O. Abdel-Wahab,et al.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. , 2014, Blood.

[7]  A. von Deimling,et al.  BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease , 2014, Annals of the rheumatic diseases.

[8]  A. Brodie,et al.  Zoledronic Acid Reverses the Epithelial–Mesenchymal Transition and Inhibits Self-Renewal of Breast Cancer Cells through Inactivation of NF-κB , 2013, Molecular Cancer Therapeutics.

[9]  L. Arnaud,et al.  Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. , 2011, Blood.

[10]  W. Roberts,et al.  Treatment of skeletal Erdheim–Chester disease with zoledronic acid: case report and proposed mechanisms of action , 2006, Rheumatology International.

[11]  P. Grenier,et al.  Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. , 2006, Radiology.

[12]  Y. Kirazlı,et al.  Erdheim-Chester disease: the effect of bisphosphonate treatment--a case report. , 2005, Archives of physical medicine and rehabilitation.

[13]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[14]  F. Sim,et al.  Erdheim-Chester disease. , 2003, Orthopedics.

[15]  F. Cantatore,et al.  Extra-skeletal effects of bisphosphonates. , 2007, Joint, bone, spine : revue du rhumatisme.